Hi everyone,
Just have a look BTA with a Mcap of around $220 Million
Around $85 Million in the bank
GSK is producing now around 60 Million courses of Relenza per year
GSK gets about $20 per course so earnings of $1.2 Billion
Biota gets 7% royalty on Relenza payements
which means they will get around $84 Million per year.
And this is all without Lani and all the other products they have in the pipeline.
Biota has become a Cash cow and could become easy a target for a predator who is eyeing all that cash.
And I have not even mentioned that I do believe that GSK will increase production again as we now all know that Relenza is the only Antiviral left standing.
The capping of the share price could be from a big boy who has been trying to get hold of as much shares as possible but lucky not many holders like to part with them.
Good luck to all and I have loaded up the truck with Biota shares waiting the story to unfold.
please do your own research
jojo
- Forums
- ASX - By Stock
- BTA
- ripe of a take-over
ripe of a take-over
-
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online